Prolonged delivery of peptides
First Claim
Patent Images
1. A method for the treatment of non-insulin dependent diabetes mellitus in a mammal in need of such treatment comprising the repeated administration over an extended period of time of a compound with prolonged action after each administration, said prolonged action necessary to achieve sustained glycemic control in mammals, said compound selected from the group consisting of:
- (a) a peptide having the amino acid sequence;
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-(SEQUENCE ID NO;
(b) a peptide having the amino acid sequence;
2) Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly;
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-(SEQUENCE ID NO;
wherein X is selected from the group consisting of;
7) Glu-Phe-Ile-Ala-Trp-Leu-Val-X
(A)Lys, (B)Lys-Gly, and (C)Lys-Gly-Arg;
(c) a derivative of a polypeptide comprising the primary structureH2N—
W—
COOH
wherein W is an amino acid sequence selected from the group consisting ofHis-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-(SEQUENCE ID NO;
1) and Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly His-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-(SEQUENCE ID NO;
6) Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg
which derivative when processed in a mammal results in a polypeptide derivative having an insulinotropic activity;
(d) a derivative of a polypeptide comprising the primary structureH2N—
R—
COOH
wherein R is an amino acid sequence selected from the group consisting ofHis-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-(SEQUENCE ID NO;
2) Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly;
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-(SEQUENCE ID NO;
3) Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg;
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-(SEQUENCE ID NO;
4) and Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly;
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-(SEQUENCE ID NO;
5) Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys;
and (e) a derivative of said peptides (a) through (d) wherein said derivative is selected from the group consisting of;
(1) a pharmaceutically acceptable acid addition salt of said peptides;
(2) a pharmaceutically acceptable carboxylate salt of said peptides;
(3) a pharmaceutically acceptable alkali addition salt of said peptides;
(4) a pharmaceutically acceptable lower alkyl ester of said peptides; and
(5) a pharmaceutically acceptable amide of said peptides wherein said pharmaceutically acceptable amide is selected from the group consisting of amide, lower alkyl amide and lower dialkyl amide.
0 Assignments
0 Petitions
Accused Products
Abstract
There are disclosed methods for the treatment of non-insulin dependent diabetes mellitus in a mammal comprising the prolonged administration of GLP-1 (7-37), and related peptides. Also disclosed are compositions to prolong the administration of the peptides.
-
Citations
48 Claims
-
1. A method for the treatment of non-insulin dependent diabetes mellitus in a mammal in need of such treatment comprising the repeated administration over an extended period of time of a compound with prolonged action after each administration, said prolonged action necessary to achieve sustained glycemic control in mammals, said compound selected from the group consisting of:
-
(a) a peptide having the amino acid sequence;
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
2)Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly; (b) a peptide having the amino acid sequence;
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
7)Glu-Phe-Ile-Ala-Trp-Leu-Val-X wherein X is selected from the group consisting of;
(A) Lys, (B) Lys-Gly, and (C) Lys-Gly-Arg; (c) a derivative of a polypeptide comprising the primary structure H2N—
W—
COOH
wherein W is an amino acid sequence selected from the group consisting ofHis-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr- (SEQUENCE ID NO;
1) andLeu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly His-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr- (SEQUENCE ID NO;
6)Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg
which derivative when processed in a mammal results in a polypeptide derivative having an insulinotropic activity;
(d) a derivative of a polypeptide comprising the primary structure H2N—
R—
COOH
wherein R is an amino acid sequence selected from the group consisting ofHis-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
2)Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly; His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
3)Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg; His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
4) andGlu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly; His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
5)Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys;
and(e) a derivative of said peptides (a) through (d) wherein said derivative is selected from the group consisting of;
(1) a pharmaceutically acceptable acid addition salt of said peptides;
(2) a pharmaceutically acceptable carboxylate salt of said peptides;
(3) a pharmaceutically acceptable alkali addition salt of said peptides;
(4) a pharmaceutically acceptable lower alkyl ester of said peptides; and
(5) a pharmaceutically acceptable amide of said peptides wherein said pharmaceutically acceptable amide is selected from the group consisting of amide, lower alkyl amide and lower dialkyl amide. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8)
-
-
9. A composition of matter comprising;
-
(i) a compound selected from the group consisting of;
(a) a peptide having the amino acid sequence;
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
2)Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly; (b) a peptide having the amino acid sequence;
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
7)Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly; wherein X is selected from the group consisting of;
(A) Lys, (B) Lys-Gly, (C) Lys-Gly-Arg; (c) a derivative of a polypeptide comprising the primary structure H2N—
W—
COOH
wherein W is an amino acid sequence selected from the group consisting ofHis-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr- (SEQUENCE ID NO;
1) andLeu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly His-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr- (SEQUENCE ID NO;
6)Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg
which derivative when processed in a mammal results in a polypeptide derivative having an insulinotropic activity;
(d) a derivative of a polypeptide comprising the primary structure H2N—
R—
COOH
wherein R is an amino acid sequence selected from the group consisting ofHis-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
2)Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
3)Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
4) andGlu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
5)Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys;
a derivative of said peptides (a) through (d) wherein said derivative is selected from the group consisting of;
(1) a pharmaceutically acceptable acid addition salt of said peptides;
(2) a pharmaceutically acceptable carboxylate salt of said peptides;
(3) a pharmaceutically acceptable alkali addition salt of said peptides;
(4) a pharmaceutically acceptable lower alkyl ester of said peptides; and
(5) a pharmaceutically acceptable amide of said peptides wherein said pharmaceutically acceptable amide is selected from the group consisting of amide, lower alkyl amide and lower dialkyl amide, and (ii) a polymer capable of prolonging the action of said compound to achieve sustained glycemic control. - View Dependent Claims (10, 11, 12, 39)
-
-
13. A composition of matter comprising;
-
(i) a compound selected from the group consisting of;
(a) a peptide having the amino acid sequence;
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
2)Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly; (b) a peptide having the amino acid sequence;
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
7)Glu-Phe-Ile-Ala-Trp-Leu-Val-X wherein X is selected from the group consisting of;
(A) Lys, (B) Lys-Gly, and (C) Lys-Gly-Arg; (c) a derivative of a polypeptide comprising the primary structure H2N—
W—
COOH
wherein W is an amino acid sequence selected from the group consisting ofHis-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr- (SEQUENCE ID NO;
1) andLeu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly His-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr- (SEQUENCE ID NO;
6)Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg
which derivative when processed in a mammal results in a polypeptide derivative having an insulinotropic activity;
(d) a derivative of a polypeptide comprising the primary structure H2N—
R—
COOH
wherein R is an amino acid sequence selected from the group consisting ofHis-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
2)Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly; His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
3)Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg; His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
4) andGlu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly; His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
5)Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys;
anda derivative of said peptides (a) through (d) wherein said derivative is selected from the group consisting of;
(1) a pharmaceutically acceptable acid addition salt of said peptides;
(2) a pharmaceutically acceptable carboxylate salt of said peptides;
(3) a pharmaceutically acceptable alkali addition salt of said peptides;
(4) a pharmaceutically acceptable lower alkyl ester of said peptides; and
(5) a pharmaceutically acceptable amide of said peptides wherein said pharmaceutically acceptable amide is selected from the group consisting of amide, lower alkyl amide and lower dialkyl amide, and (ii) a pharmaceutically acceptable water-immiscible oil suspension capable of prolonging action of said compound to achieve sustained glycemic control. - View Dependent Claims (14, 15, 16, 17, 40)
-
-
18. A composition of matter comprising;
-
(i) a compound selected from the group consisting of;
(a) a peptide having the amino acid sequence;
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
2)Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly; (b) a peptide having the amino acid sequence;
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
7)Glu-Phe-Ile-Ala-Trp-Leu-Val-X wherein X is selected from the group consisting of;
(A) Lys, (B) Lys-Gly, and (C) Lys-Gly-Arg; (c) a derivative of a polypeptide comprising the primary structure H2N—
W—
COOH
wherein W is an amino acid sequence selected from the group consisting ofHis-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr- (SEQUENCE ID NO;
1) andLeu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly His-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr- (SEQUENCE ID NO;
6)Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg
which derivative when processed in a mammal results in a polypeptide derivative having an insulinotropic activity;
(d) a derivative of a polypeptide comprising the primary structure H2N—
R—
COOH
wherein R is an amino acid sequence selected from the group consisting ofHis-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
2)Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
3)Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
4) andGlu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
5);Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys
anda derivative of said peptides (a) through (d) wherein said derivative is selected from the group consisting of;
(1) a pharmaceutically acceptable acid addition salt of said peptides;
(2) a pharmaceutically acceptable carboxylate salt of said peptides;
(3) a pharmaceutically acceptable alkali addition salt of said peptides;
(4) a pharmaceutically acceptable lower alkyl ester of said peptides; and
(5) a pharmaceutically acceptable amide of said peptides wherein said pharmaceutically acceptable amide is selected from the group consisting of amide, lower alkyl amide and lower dialkyl amide, and (ii) zinc (II), which is complexed with the peptide. - View Dependent Claims (19, 20, 21, 22, 41)
-
-
23. A composition of matter comprising;
-
(i) a compound selected from the group consisting of;
(a) a peptide having the amino acid sequence;
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
2)Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly; (b) a peptide having the amino acid sequence;
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
7)Glu-Phe-Ile-Ala-Trp-Leu-Val-X wherein X is selected from the group consisting of;
(A) Lys, (B) Lys-Gly, and (C) Lys-Gly-Arg; (c) a derivative of a polypeptide comprising the primary structure H2N—
W—
COOH
wherein W is an amino acid sequence selected from the group consisting ofHis-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr- (SEQUENCE ID NO;
1) andLeu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly His-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr- (SEQUENCE ID NO;
6Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg
which derivative when processed in a mammal results in a polypeptide derivative having an insulinotropic activity;
(d) a derivative of a polypeptide comprising the primary structure H2N—
R—
COOH
wherein R is an amino acid sequence selected from the group consisting ofHis-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
2)Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
3)Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
4) andGlu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
5);Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys
anda derivative of said peptides (a) through (d) wherein said derivative is selected from the group consisting of;
(1) a pharmaceutically acceptable acid addition salt of said peptides;
(2) a pharmaceutically acceptable carboxylate salt of said peptides;
(3) a pharmaceutically acceptable alkali addition salt of said peptides;
(4) a pharmaceutically acceptable lower alkyl ester of said peptides; and
(5) a pharmaceutically acceptable amide of said peptides wherein said pharmaceutically acceptable amide is selected from the group consisting of amide, lower alkyl amide and lower dialkyl amide, and (ii) a metal selected from the group consisting of Ni (II), Co (II), Mg (II), Ca (II), K (I), Mn (II), Fe(II), and Cu(II). - View Dependent Claims (24, 42)
-
-
25. A composition of matter comprising;
-
(i) a compound selected from the group consisting of;
(a) a peptide having the amino acid sequence;
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
2)Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly; (b) a peptide having the amino acid sequence;
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
7)Glu-Phe-Ile-Ala-Trp-Leu-Val-X wherein X is selected from the group consisting of;
(A) Lys, (B) Lys-Gly, and (C) Lys-Gly-Arg; (c) a derivative of a polypeptide comprising the primary structure H2N—
W—
COOH
wherein W is an amino acid sequence selected from the group consisting ofHis-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr- (SEQUENCE ID NO;
1) andLeu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly His-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr- (SEQUENCE ID NO;
6)Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg
which derivative when processed in a mammal results in a polypeptide derivative having an insulinotropic activity;
(d) a derivative of a polypeptide comprising the primary structure H2N—
R—
COOH
wherein R is an amino acid sequence selected from the group consisting ofHis-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
2)Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly; His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
3)Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg; His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
4) andGlu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly; and His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
5)Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys;
anda derivative of said peptides (a) through (d) wherein said derivative is selected from the group consisting of;
(1) a pharmaceutically acceptable acid addition salt of said peptides;
(2) a pharmaceutically acceptable carboxylate salt of said peptides;
(3) a pharmaceutically acceptable alkali addition salt of said peptides;
(4) a pharmaceutically acceptable lower alkyl ester of said peptides; and
(5) a pharmaceutically acceptable amide of said peptides wherein said pharmaceutically acceptable amide is selected from the group consisting of amide, lower alkyl amide and lower dialkyl amide, and (ii) a basic polypeptide, wherein said composition is an aqueous suspension capable of sustained glycemic control. - View Dependent Claims (26, 43)
-
-
27. A composition of matter comprising;
-
(i) a compound selected from the group consisting of;
(a) a peptide having the amino acid sequence;
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
2);Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly; (b) a peptide having the amino acid sequence;
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
7)Glu-Phe-Ile-Ala-Trp-Leu-Val-X wherein X is selected from the group consisting of;
(A) Lys, (B) Lys-Gly, (C) Lys-Gly-Arg; (c) a derivative of a polypeptide comprising the primary structure H2N—
W—
COOH
wherein W is an amino acid sequence selected from the group consisting ofHis-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr- (SEQUENCE ID NO;
1) andLeu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly His-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr- (SEQUENCE ID NO;
6)Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg
which derivative when processed in a mammal results in a polypeptide derivative having an insulinotropic activity;
(d) a derivative of a polypeptide comprising the primary structure H2N—
R—
COOH
wherein R is an amino acid sequence selected from the group consisting ofHis-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
2);Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
3);Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
4);Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly and His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
5);Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys
anda derivative of said peptides (a) through (d) wherein said derivative is selected from the group consisting of;
(1) a pharmaceutically acceptable acid addition salt of said peptides;
(2) a pharmaceutically acceptable carboxylate salt of said peptides;
(3) a pharmaceutically acceptable alkali addition salt of said peptides;
(4) a pharmaceutically acceptable lower alkyl ester of said peptides; and
(5) a pharmaceutically acceptable amide of said peptides wherein said pharmaceutically acceptable amide is selected from the group consisting of amide, lower alkyl amide and lower dialkyl amide, and (ii) a phenolic compound, wherein said composition is an aqueous suspension capable of sustained glycemic control. - View Dependent Claims (28, 44)
-
-
29. A composition of matter comprising;
-
(i) a compound selected from the group consisting of;
(a) a peptide having the amino acid sequence;
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
2);Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly (b) a peptide having the amino acid sequence;
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
7)Glu-Phe-Ile-Ala-Trp-Leu-Val-X wherein X is selected from the group consisting of;
(A) Lys, (B) Lys-Gly, (C) Lys-Gly-Arg; (c) a derivative of a polypeptide comprising the primary structure H2N—
W—
COOH
wherein W is an amino acid sequence selected from the group consisting ofHis-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr- (SEQUENCE ID NO;
1) andLeu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly His-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr- (SEQUENCE ID NO;
6)Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg
which derivative when processed in a mammal results in a polypeptide derivative having an insulinotropic activity;
(d) a derivative of a polypeptide comprising the primary structure H2N—
R—
COOH
wherein R is an amino acid sequence selected from the group consisting ofHis-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
2);Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
3);Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
4);Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly and His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
5);Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys
anda derivative of said peptides (a) through (d) wherein said derivative is selected from the group consisting of;
(1) a pharmaceutically acceptable acid addition salt of said peptides;
(2) a pharmaceutically acceptable carboxylate salt of said peptides;
(3) a pharmaceutically acceptable alkali addition salt of said peptides;
(4) a pharmaceutically acceptable lower alkyl ester of said peptides; and
(5) a pharmaceutically acceptable amide of said peptides wherein said pharmaceutically acceptable amide is selected from the group consisting of amide, lower alkyl amide and lower dialkyl amide, and (ii) a basic polypeptide and a phenolic compound, wherein such composition is an aqueous suspension capable of sustained glycemic control. - View Dependent Claims (45)
-
-
30. A composition of matter comprising;
-
(i) a compound selected from the group consisting of;
(a) a peptide having the amino acid sequence;
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
2)Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly; (b) a peptide having the amino acid sequence;
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
7)Glu-Phe-Ile-Ala-Trp-Leu-Val-X wherein X is selected from the group consisting of;
(A) Lys, (B) Lys-Gly, and (C) Lys-Gly-Arg; (c) a derivative of a polypeptide comprising the primary structure H2N—
W—
COOH
wherein W is an amino acid sequence selected from the group consisting ofHis-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr- (SEQUENCE ID NO;
1) andLeu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly His-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr- (SEQUENCE ID NO;
6)Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg which derivative when processed in a mammal results in a polypeptide derivative having an insulinotropic activity;
(d) a derivative of a polypeptide comprising the primary structure H2N—
R—
COOH
wherein R is an amino acid sequence selected from the group consisting ofHis-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
2)Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly; His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
3)Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg; His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
4)Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly; and His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
5)Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys;
anda derivative of said peptides (a) through (d) wherein said derivative is selected from the group consisting of;
(1) a pharmaceutically acceptable acid addition salt of said peptides;
(2) a pharmaceutically acceptable carboxylate salt of said peptides;
(3) a pharmaceutically acceptable alkali addition salt of said peptides;
(4) a pharmaceutically acceptable lower alkyl ester of said peptides; and
(5) a pharmaceutically acceptable amide of said peptides wherein said pharmaceutically acceptable amide is selected from the group consisting of amide, lower alkyl amide and lower dialkyl amide, and (ii) a basic polypeptide, a phenolic compound, and a metal ion wherein said composition is an aqueous suspension capable of sustained glycemic control. - View Dependent Claims (31, 32, 46)
-
-
33. A composition of matter comprising;
-
(i) a compound selected from the group consisting of;
(a) a peptide having the amino acid sequence;
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
2);Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly (b) a peptide having the amino acid sequence;
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala- (SEQUENCE ID NO;
7)Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-X wherein X is selected from the group consisting of;
(A) Lys, (B) Lys-Gly, (C) Lys-Gly-Arg; (c) a derivative of a polypeptide comprising the primary structure H2N—
W—
COOH
wherein W is an amino acid sequence selected from the group consisting ofHis-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr- (SEQUENCE ID NO;
1) andLeu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly His-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr- (SEQUENCE ID NO;
6)Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg
which derivative when processed in a mammal results in a polypeptide derivative having an insulinotropic activity;
(d) a derivative of a polypeptide comprising the primary structure H2N—
R—
COOH
wherein R is an amino acid sequence selected from the group consisting ofHis-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
2);Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
3);Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
4);Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly and His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
5);Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys
anda derivative of said peptides (a) through (d) wherein said derivative is selected from the group consisting of;
(1) a pharmaceutically acceptable acid addition salt of said peptides;
(2) a pharmaceutically acceptable carboxylate salt of said peptides;
(3) a pharmaceutically acceptable alkali addition salt of said peptides;
(4) a pharmaceutically acceptable lower alkyl ester of said peptides; and
(5) a pharmaceutically acceptable amide of said peptides wherein said pharmaceutically acceptable amide is selected from the group consisting of amide, lower alkyl amide and lower dialkyl amide, and (ii) said peptides and derivatives thereof having being subjected to conditions resulting in amorphous or crystalline material formation. - View Dependent Claims (34, 35, 47)
-
-
36. A composition of matter comprising;
-
(i) a compound selected from the group consisting of;
(a) a peptide having the amino acid sequence;
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
2)Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly; (b) a peptide having the amino acid sequence;
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
7)Glu-Phe-Ile-Ala-Trp-Leu-Val-X wherein X is selected from the group consisting of;
(A) Lys, (B) Lys-Gly, and (C) Lys-Gly-Arg; (c) a derivative of a polypeptide comprising the primary structure H2N—
W—
COOH
wherein W is an amino acid sequence selected from the group consisting ofHis-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr- (SEQUENCE ID NO;
1) andLeu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly His-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr- (SEQUENCE ID NO;
6)Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg
which derivative when processed in a mammal results in a polypeptide derivative having an insulinotropic activity;
(d) a derivative of a polypeptide comprising the primary structure H2N—
R—
COOH
wherein R is an amino acid sequence selected from the group consisting ofHis-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
2)Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly; His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
3)Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg; His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
4) andGlu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly; His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys- (SEQUENCE ID NO;
5)Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys;
anda derivative of said peptides (a) through (d) wherein said derivative is selected from the group consisting of;
(1) a pharmaceutically acceptable acid addition salt of said peptides;
(2) a pharmaceutically acceptable carboxylate salt of said peptides;
(3) a pharmaceutically acceptable alkali addition salt of said peptides;
(4) a pharmaceutically acceptable lower alkyl ester of said peptides; and
(5) a pharmaceutically acceptable amide of said peptides wherein said pharmaceutically acceptable amide is selected from the group consisting of amide, lower alkyl amide and lower dialkyl amide, and (ii) a liposome delivery system capable of sustained glycemic control. - View Dependent Claims (37, 38, 48)
-
Specification